Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02338050 · ClinicalTrials.gov registry record · Phase 2
Moxetumomab Pasudotox (CAT-8015, HA22) in Children With B-lineage Acute Lymphoblastic Leukemia and Minimal Residual Disease Prior to Allogeneic Hematopoietic Stem Cell Transplantation
A Phase 2 study, sponsored by Center for International Blood and Marrow Transplant Research.
- Terminated
- Registry status
- Phase 2
- Development phase
- 1
- Enrollment target
NCT02338050 is a Phase 2 study that was terminated before completion, run by Center for International Blood and Marrow Transplant Research. The registered enrollment target is 1 participants.
The verdict
NCT02338050, a Phase 2 study, was terminated before completion, sponsored by Center for International Blood and Marrow Transplant Research.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 1 participants
- Enrollment target
Study Summary
This is a phase II, open-label, nonrandomized, prospective study to evaluate the activity, safety, and feasibility of administration of moxetumomab pasudotox in the pre-allogeneic hematopoietic cell transplantation (HCT) setting to patients with B-lineage Acute Lymphoblastic Leukemia (ALL) who are in a morphologic complete remission and have pre-transplant minimal residual disease (MRD) \> 0.01% (detected by flow cytometry). The primary objective of this study is to determine if treatment with moxetumomab pasudotox in the MRD positive setting is able to lead to MRD negativity (\< 0.01% by flow cytometry) or at least a 1-log10 reduction in MRD prior to allogeneic HCT.
Interventions
- BIOLOGICAL Moxetumomab Pasudotox
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1 participants |
| Start Date | 2015-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02338050
The ClinicalTrials.gov registry entry for NCT02338050 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 1 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Center for International Blood and Marrow Transplant Research, which has 29 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Moxetumomab Pasudotox is the first listed.
NCT02338050 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02338050 about?
NCT02338050 is a clinical study titled "Moxetumomab Pasudotox (CAT-8015, HA22) in Children With B-lineage Acute Lymphoblastic Leukemia and Minimal Residual Disease Prior to Allogeneic Hematopoietic Stem Cell Transplantation". This is a phase II, open-label, nonrandomized, prospective study to evaluate the activity, safety, and feasibility of administration of moxetumomab pasudotox in the pre-allogeneic hematopoietic cell transplantation (HCT) setting to patients with B-lineage Acute Lymphoblastic Leukemia (ALL) who are i...
What is the current status of trial NCT02338050?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 1 participants. The study started on 2015-05.
What interventions are being tested in trial NCT02338050?
The interventions under investigation include: Moxetumomab Pasudotox (BIOLOGICAL).
Who is sponsoring clinical trial NCT02338050?
This trial is sponsored by Center for International Blood and Marrow Transplant Research, which has 29 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.